Todd R. Patrick appointed president of ID Vaccine Corporation.
Mr. Patrick has held the position of Vice President, Business Development of ID Vaccine since joining the company in July 1994. Prior to joining ID Vaccine, he was the Director of the UCLA Office of Intellectual Property Administration, a position he held for approximately five years, and prior to UCLA, the Executive Director of the Washington State University Research Foundation ("WSURF").
"With the completion of the strategic alliance with Pasteur Merieux- Connaught on our TB vaccine, we believe that ID Vaccine is now well positioned to expand its products under development," said Frank Holler, ID Biomedical's President and CEO. "Mr. Patrick's appointment evidences IDB's commitment to develop ID Vaccine into an autonomously managed subsidiary."
Mr. Patrick has a BA in Economics from the University of Washington and a MAsters of Business Administration from Washington State University. He is a member of the WSURF Board of Trustees, the Licensing Executive Society and the Association of University Technology Managers.
ID Biomedical Corporation is a Canadian biotechnology company which is developing a nucleic acid diagnostic system and related products based on its proprietary SLT and CPT technologies. Directly and through its collaborations, IDB's research programs include tests for seven infectious diseases, a cancer and a genetic disease. ID Vaccine Corporation is a subsidiary of IDB, and is engaged in the development of subunit vaccines and immunotherapeutics against infectious diseases. -0- NOTE TO EDITORS: Neither NASDAQ, The Montreal Exchange nor the Vancouver Stock Exchange has approved or disapproved of the information contained herein.
CONTACT: Hugh Notman, 604/431-9314